Loading...
XSWX
BANB
Market cap4.06bUSD
Apr 04, Last price  
46.62CHF
1D
-5.70%
1Q
-20.98%
Jan 2017
-48.37%
Name

Bachem Holding AG

Chart & Performance

D1W1MN
P/E
29.07
P/S
5.77
EPS
1.60
Div Yield, %
1.72%
Shrs. gr., 5y
1.72%
Rev. gr., 5y
14.05%
Revenues
605m
+4.84%
153,656,000171,754,000198,318,000194,997,000181,848,000152,884,000145,808,000157,298,000170,685,000183,937,000208,604,000236,478,000261,612,000282,500,000313,715,000401,995,000503,234,000531,741,000577,316,000605,259,000
Net income
120m
+7.50%
39,232,00046,649,00063,927,00058,709,00046,057,00028,297,0009,409,00015,300,00023,604,00029,065,00031,838,00041,205,00041,770,00046,644,00054,164,00078,062,000114,682,000100,684,000111,859,000120,248,000
CFO
146m
-41.44%
27,423,00040,150,00078,070,00039,277,00042,847,00038,110,00024,609,00036,871,00049,230,00047,218,00061,434,00040,409,00036,479,00025,776,00063,648,000114,628,00097,163,00092,589,000249,864,000146,322,000
Dividend
May 05, 20250 CHF/sh
Earnings
Jul 24, 2025

Profile

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
URL
https://www.bachem.com/
IPO date
Jun 29, 2001
Employees
1,926
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
605,259
4.84%
577,316
8.57%
531,741
5.66%
Cost of revenue
473,316
448,754
405,428
Unusual Expense (Income)
NOPBT
131,943
128,562
126,313
NOPBT Margin
21.80%
22.27%
23.75%
Operating Taxes
14,961
12,349
11,390
Tax Rate
11.34%
9.61%
9.02%
NOPAT
116,982
116,213
114,923
Net income
120,248
7.50%
111,859
11.10%
100,684
-12.21%
Dividends
(59,990)
(56,236)
(51,620)
Dividend yield
1.38%
1.16%
0.88%
Proceeds from repurchase of equity
(1,057)
105,282
33,944
BB yield
0.02%
-2.17%
-0.58%
Debt
Debt current
162
339
Long-term debt
418
436
704
Deferred revenue
(49,076)
Other long-term liabilities
192,988
145,561
49,076
Net debt
(94,617)
(298,091)
(267,384)
Cash flow
Cash from operating activities
146,322
249,864
92,589
CAPEX
(273,841)
(268,402)
(142,344)
Cash from investing activities
(148,882)
(170,807)
(63,166)
Cash from financing activities
(61,256)
48,689
(86,932)
FCF
(199,975)
(162,873)
(89,582)
Balance
Cash
95,197
298,527
268,427
Long term investments
Excess cash
64,934
269,661
241,840
Stockholders' equity
802,730
658,120
587,733
Invested Capital
1,519,433
1,196,641
917,378
ROIC
8.61%
10.99%
14.02%
ROCE
8.03%
8.47%
10.45%
EV
Common stock shares outstanding
75,327
74,688
73,735
Price
57.90
-10.92%
65.00
-18.60%
79.85
-88.85%
Market cap
4,361,438
-10.16%
4,854,750
-17.54%
5,887,709
-88.39%
EV
4,266,821
4,556,659
5,620,325
EBITDA
175,205
165,918
159,631
EV/EBITDA
24.35
27.46
35.21
Interest
50
367
719
Interest/NOPBT
0.04%
0.29%
0.57%